Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET.
We recently demonstrated the feasibility of combining enhanced tumor-to-tissue contrast and PET imaging for immunoscintigraphic tumor localization in pancreas and colon carcinoma bearing nude mice. Contrast enhancement was obtained with a multistep targeting technique that consists of the sequential administration of an antitumor/antihapten bispecific antibody (BS-MAb), a blocker to saturate the antihapten binding sites of the BS-MAb that remains in circulation, and a low molecular weight Ga chelate, labeled with the positron emitter 68Ga, which serves as the hapten. To evaluate the efficacy of this pretargeting technique for breast cancer localization, we synthesized a BS-MAb from the F(ab')(2) fragments of the anti-MUC1 MAb 12H12 which reacts with the vast majority of human breast carcinomas, and the F(ab') fragment of an anti-Ga chelate MAb using a bifunctional chemical linker. The BS-MAb was tested for its affinity and its biokinetics in nude mice bearing a human mammary carcinoma. Equilibrium binding of the BS-MAb for mammary carcinoma cells was low (1.2 x 10(7) M(-1)) while the binding capacity of cells was high (8.4 x 10(6) BS-MAbs per cell). Tumor uptake of the 67Ga labeled chelate in pretargeted animals was to 5.8 +/- 0.8% iD/g resulting in a tumor-to-blood ratio of 2.6 at 1h postinjection. This compares with a ratio of 0.65 and 0.85 obtained with 125I-labeled native 12H12 at 24h and 48h postinjection. No difference in the tumor uptake of both the 68Ga and 67Ga labeled chelate was observed. PET imaging of mice, started 1h postinjection of the 68Ga chelate, clearly visualized all tumors.
Schuhmacher
J
J
Department of Diagnostic and Therapeutic Radiology German Cancer Research Center, Heidelberg, Germany.
Klivényi
G
G
Kaul
S
S
Henze
M
M
Matys
R
R
Hauser
H
H
Clorius
J
J
D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics; D002614:Chelating Agents; D005260:Female; D005708:Gallium / Q000737:chemistry*; D007202:Indicators and Reagents; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging*; D051379:Mice; D008819:Mice, Nude; D018396:Mucin-1 / Q000276:immunology*; D009077:Mucins / Q000276:immunology*; D009368:Neoplasm Transplantation; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013667:Technetium; D014018:Tissue Distribution; D014055:Tomography, Emission-Computed
D000911:Antibodies, Monoclonal; D002614:Chelating Agents; D007202:Indicators and Reagents; D007205:Indium Radioisotopes; D007457:Iodine Radioisotopes; D018396:Mucin-1; D009077:Mucins; D019275:Radiopharmaceuticals; D013667:Technetium; D005708:Gallium